BeiGene's Q1 Loss Narrows as Revenue Rises
BeiGene (BGNE) reported a Q1 loss Wednesday of $2.41 per American depository share, narrowing from a loss of $3.34 a year earlier. Analysts polled by Capital IQ expected a loss of $2.89. Revenue for t
BeiGene GAAP EPADS of -$2.41 Beats by $0.48, Revenue of $751.65M Beats by $76.42M
10-Q: Quarterly report
BeiGene Q1 2024 GAAP EPADS $(2.41) Beats $(2.89) Estimate, Sales $751.652M Beat $676.451M Estimate
BeiGene (NASDAQ:BGNE) reported quarterly losses of $(2.41) per share which beat the analyst consensus estimate of $(2.89) by 16.61 percent. This is a 27.84 percent increase over losses of $(3.34) per
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M
06:04 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M
BeiGene 1Q Loss/Shr 19c >BGNE
BeiGene 1Q Loss/Shr 19c >BGNE
BeiGene 1Q Loss $251.2M >BGNE
BeiGene 1Q Loss $251.2M >BGNE
BeiGene 1Q Rev $752M >BGNE
BeiGene 1Q Rev $752M >BGNE
Press Release: BeiGene Reports First Quarter 2024 Financial Results and Business Updates
BeiGene Reports First Quarter 2024 Financial Results and Business Updates -- Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase
Hong Kong Stock Concept Tracking | BMS's PD- (L) 1 Hypodermic Injection Listed in US Newspaper to Actively Promote Domestic Innovative Drugs (with concept stocks)
On May 6, BMS announced that the O Drug Subcutaneous Biological Product License Application (BLA) has been accepted by the FDA for all solid tumor indications previously approved by Opdivo for marketing
BeiGene (06160.HK) issued 155,900 shares due to restricted share units
On May 2, GLONGHUI (06160.HK) issued an announcement. On April 30, 2024, 155,900 common shares will be issued due to the ownership of restricted share units granted under the equity plan (excluding company directors).
BeiGene (06160) issued 261.82 million shares under the share award scheme on April 30
According to the Zhitong Finance App, BeiGene (06160) announced that 261.82 million shares will be issued under the share award program on April 30, 2024.
BeiGene PD-1 inhibitor Baizean approved 13th application for indication in China
China National Drug Administration (NMPA) approves Baize'an (tirelizumab) as a new indication for gastric cancer, Beijing, April 30, 2024/4/2024/PRNewswire/ -- BeiGene (NASDAQ: BGNE; Hong Kong Stock Exchange code: 06160; Shanghai Stock Exchange code: 688235), a global cancer treatment innovation company, announced today that its PD-1 inhibitor baizean (tirelizumab) has been officially approved by China's National Drug Administration (China Drug Administration) in combination with fluorouracil and platinum chemotherapeutics For advanced local use, unresectable or metastatic stomach or stomach eating
BeiGene issued approximately 238,600 shares due to the ownership of restricted share units
BeiGene (06160) announced that on April 29, 2024, approximately 238,600 shares were issued due to the ownership of restricted share units granted under the equity plan.
BeiGene (06160.HK) issued 238,600 shares due to restricted share units
On April 30, GLONGHUI | BeiGene (06160.HK) issued an announcement. On April 29, 2024, 238,600 common shares were issued due to the ownership of restricted share units granted under the equity plan (excluding company directors).
BeiGene issued approximately 121,000 shares due to the ownership of restricted share units
BeiGene (06160) announced that on April 28, 2024, approximately 121,000 shares were issued due to the ownership of restricted share units granted under the equity plan.
BeiGene (06160) issued approximately 121,000 shares due to the ownership of restricted share units
BeiGene (06160) announced that on April 28, 2024, due to a restricted share list granted under an equity plan...
Tracking Last Week's Top Performers: Are These 15 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
With the earnings season in full swing, these large-cap stocks were the best performers in the last week. Are they in your portfolio?Vertiv Holdings Co (NYSE:VRT) increased 23.3% after it reported bet
US MOVERS&SHAKERS Apr 22-Apr 26, 2024
Here are the top 10 gainers and losers of the week.
BeiGene (NASDAQ:BGNE) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
No Data